Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Branebrutinib in active systemic lupus erythematosus or primary Sjögren's syndrome; branebrutinib followed by open-label abatacept in active rheumatoid arthritis
2019-002205-22Phase 2Unknown
- Sponsor
- Bristol Myers Squibb
- Start
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of branebrutinib in systemic lupus erythematosus (SLE), primary Sjögren's syndrome and rheumatoid arthritis (RA) (3 arms), sponsored by Bristol Myers Squibb. Primary endpoint: mCLASI activity score response in SLE. Status: unknown.
02
Drugs
branebrutinib
03
Conditions
systemic lupus erythematosus (SLE)primary Sjögren's syndromerheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2019-002205-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002205-22.